Earnings Ahead

BWAY - Brainsway Ltd.

Brainsway Ltd.

Brainsway Ltd.

About

Profile

BrainsWay is dedicated to developing and providing advanced technology solutions for the treatment of a variety of brain disorders. The company was established in 2003, and became a public company traded on the Tel-Aviv Stock Exchange in January 2007. BrainsWay’s flagship technology is Deep-TMS, or Deep Transcranial Magnetic Stimulation, which launches a new era in brain disorder treatment.


Headquarters

Jerusalem, Israel


Intraday

High
-
Low
-

52-week

High
-
Low
-

BWAY

Recent Earnings

Brainsway GAAP EPS of -$0.15 misses by $0.09, revenue of $5.17M misses by $3.28M



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Brainsway GAAP EPS of -$0.15 misses by $0.09, revenue of $5.17M misses by $3.28M
  • BrainsWay gets significant private insurance coverage from Cigna for OCD treatment Utilizing Deep TMS
  • BrainsWay adds 20% on FDA nod for depression therapy
  • Brainsway GAAP EPS of -$0.07 in-line, revenue of $8.01M misses by $0.41M
  • Brainsway announces insurance coverage by Israeli Ministry of Health
  • Brainsway GAAP EPS of -$0.06 beats by $0.01, revenue of $8M beats by $0.6M
  • Brainsway GAAP EPS of -$0.04 beats by $0.02, revenue of $8.47M beats by $0.23M
  • BrainsWay gets local coverage determination for BrainsWay Deep TMS to treat OCD
  • Brainsway EPS beats by $0.01, beats on revenue
  • BrainsWay shares climb 20% after FDA's Deep TMS system 510k clearance
  • Brainsway EPS beats by $0.13, beats on revenue
  • Brainsway EPS misses by $0.03, beats on revenue
  • BrainsWay launches noninvasive treatment for smoking addiction
  • BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment
  • Brainsway EPS beats by $0.03, beats on revenue
  • BrainsWay readies ADS offering
  • BrainsWay shares fall despite supply deal with Gaelan Medical for Deep TMS
  • Brainsway +4% on Q3 beat, bottom-line up 66%
  • Brainsway EPS beats by $0.02, beats on revenue
  • FDA OKs BrainsWay TMS system for smoking addiction
Recent Earnings

Brainsway GAAP EPS of -$0.15 misses by $0.09, revenue of $5.17M misses by $3.28M

Earnings History

Date EPS / Forecast Revenue / Forecast
November 17, 2021 -0.05 / -0.062 8.06M / 6.83M Beat!
August 11, 2021 -0.06 / -0.066 7.01M / 6.25M Beat!
May 20, 2021 -0.11 / -0.076 6.12M / 5.81M Beat!
March 24, 2021 -0.02 / -0.05 7.07M / 6.94M Beat!
November 18, 2020 -0.04 / -0.0575 6.01M / 5.45M Beat!
August 12, 2020 -0.03 / -0.12 4.82M / 4.78M Beat!
June 24, 2020 -0.15 / -0.15 4.16M / 4.55M
May 27, 2020 -0.16 / -0.15 4.6M / 4.8M
March 23, 2020 -0.1 / -0.12 6.29M / 6.2M Beat!
November 25, 2019 -0.12 / -0.13 5.93M / 5.75M Beat!
August 26, 2019 -0.17 / -0.11 5.7M / 5.4M Beat!
May 29, 2019 -0.11 / -0.13 5.18M / 5.14M Beat!
February 27, 2019 -0.13 / - 4.75M / - Beat!
Date Price Open High Low Vol Change ER
Mar 9 7.59 7.69
7.79
7.47
34.70K -4.89%
Mar 8 7.98 7.56
7.98
7.38
14.49K 8.93%
Mar 7 7.33 7.32
7.35
7.30
2.00K -1.53%
Mar 4 7.44 7.62
7.62
7.44
3.06K -2.87%
Mar 3 7.66 7.91
7.91
7.52
16.64K -0.91%
 
Mar 2 7.73 7.84
7.84
7.69
3.30K -1.53%
Mar 1 7.85 7.97
7.98
7.60
6.94K 0.96%
Feb 28 7.78 7.76
7.84
7.68
8.26K -2.39%
Feb 25 7.97 7.99
8.00
7.80
10.07K 1.53%
Feb 24 7.84 7.60
7.98
7.26
14.32K 0.19%
Feb 23 7.83 8.01
8.05
7.68
8.41K -0.76%
Feb 22 7.89 7.77
8.10
7.77
856.62K -1.38%
Feb 18 8.00 8.12
8.12
8.00
1.97K -4.08%
Feb 17 8.34 8.00
8.34
7.96
10.16K 6.11%
Feb 16 7.86 7.77
7.91
7.77
11.40K 1.16%
Feb 15 7.77 7.49
7.77
7.49
6.60K 7.47%
Feb 14 7.23 7.44
7.46
7.23
3.44K -4.93%
Feb 11 7.61 7.39
7.71
7.39
5.00K -1.74%
Feb 10 7.74 7.75
7.78
7.65
2.26K -0.39%